Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKesson
Colorcon
McKinsey
Express Scripts

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR PRAZOSIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Prazosin Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00487032 ↗ Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation Completed Brian J Lipworth Phase 4 2008-05-01 The investigators wish to evaluate the onset of tolerance to nasal decongestants like oxymetazoline (available over the counter) and the mechanism of tolerance particularly with differential effects on alpha 1 and alpha 2 adrenoreceptors on the nose. The investigators will 'tease' out by using an alpha 1 blocker called Prazosin. The investigators hypothesize that alpha 1 receptors mediate arterial constriction and this will be captured by measuring nasal blood flow. The investigators also hypothesize that alpha 2 receptors mediate venous sinusoid constriction and this the investigators will capture by airflow parameters like Peak Nasal Inspiratory Flow, Rhinomanometry, Oscillometric indices etc.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Prazosin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00108420 ↗ Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance Completed US Department of Veterans Affairs Phase 4 2003-10-01 The purpose of this study is to determine whether prazosin will reduce the incidence of nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals with PTSD.
NCT00108420 ↗ Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance Completed VA Office of Research and Development Phase 4 2003-10-01 The purpose of this study is to determine whether prazosin will reduce the incidence of nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals with PTSD.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Prazosin Hydrochloride

Condition Name

Condition Name for Prazosin Hydrochloride
Intervention Trials
Posttraumatic Stress Disorder 9
PTSD 7
Stress Disorders, Post-Traumatic 7
Hypertension 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Prazosin Hydrochloride
Intervention Trials
Stress Disorders, Post-Traumatic 25
Stress Disorders, Traumatic 18
Disease 17
Alcoholism 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Prazosin Hydrochloride

Trials by Country

Trials by Country for Prazosin Hydrochloride
Location Trials
United States 94
Canada 5
France 3
United Kingdom 2
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Prazosin Hydrochloride
Location Trials
Washington 22
California 6
Connecticut 5
Texas 4
Wisconsin 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Prazosin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Prazosin Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 6
Phase 2 15
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Prazosin Hydrochloride
Clinical Trial Phase Trials
Completed 36
Recruiting 11
Withdrawn 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Prazosin Hydrochloride

Sponsor Name

Sponsor Name for Prazosin Hydrochloride
Sponsor Trials
VA Office of Research and Development 12
Seattle Institute for Biomedical and Clinical Research 9
VA Puget Sound Health Care System 9
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Prazosin Hydrochloride
Sponsor Trials
Other 63
U.S. Fed 36
NIH 17
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Harvard Business School
Dow
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.